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1. Introduction
out and other inflammatory diseases such as 
rheumatoid arthritis (RA), hypertension and 
diabetes mellitus are characterized by high uric 
acid level in blood (1, 2). These diseases are described by 
frequent occurrences of acute inflammatory arthritis 
caused by the precipitation of uric acid in the joints and 
neighboring soft tissues. The blood uric acid levels (as a 
final metabolite of purines) depend on the function of 
the kidneys especially in a purine-rich diet (2). 
Xanthine oxidase (XO, EC 1.17.3.2) is the enzyme (MW 
285 KD) which belongs to the family of xanthine 
oxidoreductase. This enzyme can catalyze hypoxanthine 
oxidation to xanthine, and further to uric acid and 
generates reactive oxygen species (ROS) such as free 
superoxide radicals and hydrogen peroxide (3, 4). 
Frequent and high intake of pruine-rich foods seem to be 
associated with activation and liberation of XO. 
Therefore, the treatment of gout and other related 
diseases can be achieved by inhibiting high activity of this 
enzyme (5). Allopurinol is the only available drug as a 
xanthine oxidase inhibitor that decreases the production 
of uric acid and has side effects such as Steven-Johnson 
syndrome (SJS), allopurinol hypersensitivity syndrome 
(AHS), and nephrotoxicity (3, 6). Therefore, the 
discovery and development of new XO inhibitors with 
fewer adverse and side effects is considered an important 
area of research within the contemporary drug discovery 
scenario. 
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Some 1,4-dihydropyridine (DHP) derivatives have been 
shown to reduce the intracellular production of reactive 
oxygen species (ROS) (7). The aim of this study was to 
evaluate a few derivatives of DHP in terms of cytotoxicity 
and XO inhibitory potential (8-11). Previous 
investigations demonstrated several biological activities 
of DHP derivatives such as calcium channel blocker 
(CCBs) (12), antioxidant (13), anticonvulsant (14), 
antitumor (15) and anti-inflammatory (16) whereas 
some of them including amlodipine, nifedipine, 
lecarnidipine and cilinidipine have been widely applied 
as therapeutic agents (17). Despite the beneficial 
biological activities of DHPs, some reports indicated that 
these compounds possessed relatively intrinsic 
cytotoxicity. The results of some studies showed that the 
intrinsic cytotoxicity of DHPs could favorably be used 
against cancer cells (17, 18). By modifying the structure 
of some relevant derivatives, it might be possible to 
reduce the property of blocking of calcium channels 
effect and hence increase their level of selective toxicity 
against cancer cells (8, 17, 19, 20). Another application 
of DHPs and their derivatives is their usage as anti-
multidrug resistance (MDR) agents. MDR is a serious 
health problem in simultaneous administration of 
multiple drugs for cancer treatment. The reason of MDR 
is the over-expression of P-glycoprotein in cancer cells, 
which leads to its more activity and then reduces the 
accumulation of drugs in cancer cells and finally 
increases the drug resistance cancer cells.  Recently, it has 
been discovered that the new derivatives of DHPs have a 
significant role in inhibition of p-glycoproteins and 
hence can act as potential tumor chemo-sensitizers (20, 
21). The use of computational methods to estimate and 
model the activity of different molecules increases the 
pace of drug discovery and development.  
Today, molecular docking tools are considered essential 
and has been used widely for the rational design of drugs 
and this technique is based on molecular structure and 
interactions between two molecules (protein-protein or 
protein-ligand). In this technique, structure of a small 
molecule or drug is randomly changed in terms of 
translation, torsion and conformation search algorithms 
at the macromolecule level with the aim of finalizing the 
ideal location for connecting to macromolecule (22). 
The interactions of the new derivatives of DHP as small 
molecule with XO as a macromolecule target have been 
explored through molecular docking (5, 6, 23, 24). In this 
study, the inhibitory activity and cytotoxicity of three 
1,4-DHP derivatives (A-C) were assessed by 
spectrophotometric analysis and MTT assay on MCF-7 
and L929 cells, respectively. Moreover, molecular 
docking studies were conducted on candidate structures 
to explore the binding features within XO binding sites. 
2. Material and Methods 
Two previously identified compounds (A and B) consist 
of 2,6-dimethyl-3,5-bis-N-(2-benzothiazolyl) 
carbamoyl-4-(4-methoxyphenyl)-1,4-dihydropyridine 
and 2,6-dimethyl-3,5-bis-N-(2-benzothiazolyl) 
carbamoyl-4-(3-nitrophenyl)-1,4-dihydropyridine were 
synthesized according to the Hantzsch reaction (11, 25), 
while 2,6-dimethyl-3,5-bis-N-(2-benzothiazolyl) 
carbamoyl-4-(4-chloro-3-nitrophenyl)-1,4-
dihydropyridine (C; Fig 1) was synthesized at this study. 
For this purpose, in a 100 ml round-bottom ﬂask 1 mmol 
4-chloro-3-nitrophenyl was added to 2 mmol of N-aryl 
acetamide and 2 mmol AcONH4. Absolute ethanol (20 
ml) was used as a solvent and the mixture was refluxed 
with stirring for 48 h at 80 °C. The progress of the 
reaction and purity of the products were monitored by 
thin-layer chromatography (TLC) which supported by 
Merck silica gel 60 F254 aluminum plates. After the 
reaction is completed, the mixture was condensed under 
reduced pressure and washed tree times with cooled 
ethanol. The final product was separated and re-
crystallized three times from ethanol. The structure of 
the synthesized compound was confirmed by 1HNMR 
(A-380, Bruker, USA) and Fourier-transform infrared 
spectroscopy (FTIR) (8400S, Shimadzu, Japan) while for 
two other derivatives, spectroscopic properties were 
compared and confirmed with previous reports. 
 
 
Figure 1. Chemical structure of assessed dihydropyridine derivatives 
(A: R1=OCH3, R2=H, B: R1=H, R2=NO2, C: R1=Cl, R2=NO2) 
 
2.1. Synthesis of 2,6-dimethyl-3,5-bis-N-(2-
benzothiazolyl) carbamoyl-4-(4-chloro-3-nitrophenyl)-
1,4 dihydropyridine (C) 
Pale yellow powder, Yield 63%, FTIR (KBr, cm-1) 3412 
(N–H, DHP), 3066 (C–H, aliphatic), 1708 (C=O, amide), 
1599 (C=C, alkene), 1HNMR (DMSO-d6) δ (ppm) 12.10 
(2H, brs, NH-amide), 9.19 (1H, brs, NH-DHP), 8.03 (1H, 
d, J = 7.6 Hz, CH-phenyl), 7.89 (IH, s, CH-phenyl), 7.82 
(1H, d, J = 8 Hz, CH-phenyl), 7.76 (2H, d, J = 8.4 Hz, 
C4′H-benzothiazole), 7.56 (2H, d, J = 8.4 Hz, C7′H-
benzothiazole), 7.52 (2H, t, J = 8.4 Hz, C6′H-
benzothiazole), 7.38 (2H, t, J = 8 Hz, C5′H-
benzothiazole), 5.53 (1H, s, C4H-DHP), 2.36 (6H, s, 
CH3-DHP).  
 
2.2. Biological Assessment 
2.2.1. Methyl thiazolyl tetrazolium (MTT) Assay 
Cell toxic activity of the synthesized compounds were 
assessed by their cytotoxic effects using MTT assay 
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method against two cell lines L929 (the parent L strain 
was derived from normal subcutaneous areolar and 
adipose tissue of a 100-day-old male C3H/An mouse, 
this cell line can be widely used for toxicity testing) and 
MCF-7 (as human breast cancer cell line) (8, 19, 26) 
which were purchased from Pasteur institute, Iran. 
MCF-7 and L929 cells were cultured in RPMI-1640 
medium containing 10% FBS in a wet atmosphere of CO2 
(5%) at 37 °C, 100 U/ml penicillin, and 100 µg/mL 
streptomycin, then cells were trypsinized in and then 
seeded into plastic 96-well plates at a density of 5000-
10000 cells per well and incubated for 24 and 48 hours. 
Serial concentrations of compounds (5, 10, 20, 40, 60, 80, 
and 100 µg/ml) were prepared in RPMI media using 
dimethyl sulfoxide (DMSO) as co-solvent. Samples were 
further incubated for 48 hours and the assay was started 
with 20 µl of MTT reagent (Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (5 mg/ml) and incubated 
for 4 hours at 37 °C. After removing the reagent and cell 
culture medium, 200 µl of DMSO was added to dissolve 
the forming formazan crystals. The spectrophotometric 
absorbance of the samples was recorded using an ELISA 
reader at 570 nm (Thermo, USA). 
2.2.2. Preparation of Xanthine Oxidase Enzyme 
Enzyme preparation was conducted in accordance to the 
method of Johnson et al. (27). Briefly, the rat was killed 
by cervical dislocation, and then its liver was 
immediately separated and located in a mixture of water 
and ice containing isotonic potassium chloride solution 
(1.15% KCl w/v) and 0.1 mM EDTA. Then, the sample 
was homogenized at 4000-5000 rpm for 4 min at 4 °C 
using Potters homogenizer. The homogenate was heated 
in a steam bath at 55-57 °C for 15 min, cooled down to 4 
°C and centrifuged at 15000 g for 45 min at 4 °C, and then 
the saturated solution of ammonium sulphate (50%, 35.3 
g/100 ml) was added to supernatant fluid at 4 °C. The 
resulting suspension was centrifuged at 6000 g for 20 min 
at 4 °C. The precipitate was then dissolved in 500 ml of 
0.1 mM EDTA solution and then was frozen until use. 
The Ethics Committee of Tabriz University of Medical 
Sciences approved the study (Code of ethics committee: 
IR.TBZMED.REC.1395.146). 
2.2.3. Enzyme Assays  
The XO enzyme activity and the inhibition activity of it 
by DHP derivatives were carried out at 37 °C using a 
Shimadzu 2550 UV/VIS spectrophotometer which was 
connected to cell temperature control unit (Shimadzu 
UV Probe personal software). XO activity was 
determined by using xanthine (50 mM) as a specific 
substrate, allopurinol (50 mM) as a xanthine oxidase 
inhibitor (control test) by monitoring absorbance 
changes at 296 nm.  The substrate was dissolved in 
Sorenson’s phosphate buffer (pH 7.0) containing 0.1 mM 
EDTA and the initial oxidation was carried out up to 2 
min. Then, the inhibition activity of DHP derivatives (A, 
B, and C at 500 µl & 50 µM) were measured. The 
inhibition activity results were also compared with the 
inhibitory effect of allopurinol (500 µl and 50 µM) as a 
control. 
2.3. Molecular Docking 
The development in any scientific field, particularly 
biology, cheminformatics, and computers as well as the 
availability of the crystallographic structures of targets 
such as proteins for three-dimensional structure of 
bioactive agents like drugs, facilitated the control of the 
diseases by scientists.  Molecular docking approach is a 
new computer-aided drug design method for predicting 
the preferred interactions and binding orientations of 
proteins with drugs that is usually compared with the 
experimental biological tests. It were considered into 
account to study the interactions between the active site 
of XO, ligands AutoDock (version 4.2) (28) and Gold 
(version 5.0) (29). Also the X-ray crystallographic 
structure of bovine XO was downloaded from Protein 
Data Bank (PDB) with the code 3NVW. The B, C, J, K, L 
chains, and all small molecules were removed from the 
protein structure, and finally the C-chain was selected for 
molecular docking procedure. Mode of molecular 
docking during this process was rigid receptor. The 
proteins and the ligands are considered respectively as 
rigid and flexible receptors (30). To perform docking 
process, several steps were done such as preparation of 
target and ligand files prior the analysis, grid box 
definition, ligands docking, and analyzing the results of 
docking experiments. Auto Grid analysis was used as an 
efficient computational method for calculating protein-
ligand for atomic affinity. Docking was carried out using 
Lamarckian genetic algorithm (LGA) which is an 
adaptive local search method (31). To perform docking 
simulations, a grid box was defined to enclose the 
binding site of XO with dimensions of 60Å×60Å×60Å 
and the grid space of 0.375 Å. The other parameters were 
set as default. According to docking results, a cluster 
analysis for the obtained 100 structures based on root 
mean square with tolerance of 0.2 nm was subsequently 
performed and the lowest energy conformation of the 
more populated cluster was selected and taken into 
account. To generate the schematic 2D representations 
of the ligand-receptor hydrogen and hydrophobic 
interactions LIGPLOT software program was used (32). 
3. Results and Discussion 
A few DHP compounds were obtained by condensation 
of various aromatic aldehydes, 2-aminobenzothiazole 
and ammonium acetate under reflux conditions in 
ethanolic solution. The structure of the synthesized 
compound was confirmed by 1HNMR in DMSO 
solution. In vitro cytotoxic activities of the synthesized 
compounds (A, B, and C) were measured by MTT assay 
method on the MCF-7 and L929 cell lines at 
concentrations 5, 10, 20, 40, 60, 80, and 100 µg/ml. The 
percentage of cell viability of MCF-7 and L929 after 24, 
48 hours incubation against concentrations of A, B, and 
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C derivatives for concentrations > 20 μM is shown in 
Table 1. It should be notified that no significant cell 
cytotoxicity could be observed at concentrations of less 
than 20 μM for DHP derivatives. 
 
Table 1. Percentage of cell viability for MCF-7 and L929 cells in the presence of A, B, and C. The cells were seeded in 96 well plate and incubated for 24 
& 48 hours. Cell viability was assessed using MTT assay 
Compound and Incubation time (h) A (24) A (48) B (24) B (48) C (24) C (48) 
MCF-7, % 57 64 33 5 60 55 
L929, % 82 64 47 5 80 73 
 
Table 2. Inhibition of Liver xanthine oxidase by compounds A and C and Allopurinol as a positive control 
Compound Inhibitor conc. (µM) Substrate IC50 (µM) Inhibition, % 
A 20 Xanthine 11.07 ± 1.46 88 
C 20 Xanthine 8.96 ± 1.40 85 
Allopurinol 100 Xanthine 2.10 ± 0.80 97.1 
The results are expressed as percentage inhibition (mean ± SD and n = 3). 
 
Table 3. Free binding energy, Ki, and Gold fitness score of 1,4-DHP derivatives (A-C and allopurinol) 
Compound Free binding energy (kcal/mol) Ki Gold fitness score 
A -8.05 1.26 µM 60.3251 
B -9.61 90.85 nM 65.2671 
C -7.93 1.55 µM 57.8462 
Allopurinol -4.47 545.56 µM - 
 
The percentages of cell viability in the presence of 
compound A were estimated as 57% and 82% at 
concentrations above 40 µg/ml for MCF-7 and L929 
cells, respectively, after 24 hours incubation, whereas 
these amounts were found to be 64% for both types of 
cell lines after 48 hours incubation. Reduced toxic effect 
of the compound A on both cell lines after 48 hours 
incubation compared to 24-hours incubation may be due 
to drugs’ low half-life and instability after 24 hours. Also 
the MTT assay results of compound B showed the 
viability percentages for both types of cell lines in the 
range of 30-35 percent at concentration above 10 µg/ml 
after 24 hours incubation. These amounts were 5 percent 
for both types of cell lines after 48 hours incubation. The 
evaluation of MTT assay results of compound C showed 
that the percentages of cell viability for both types of cell 
lines were at the range of 30-35 percent at concentration 
above 10 µg/ml after 24 hours incubation, while these 
amounts were 5 percent for both types of cell lines after 
48 hours incubation. The MTT assay results for 
compound B within both cell lines showed that the 
toxicity of compound B was more than A and C 
compounds. Therefore, it might be possible to extend the 
scope of compound B and its derivatives as potential 
pharmaceutical agents. 
3.1. Xanthine Oxidase Inhibition Assay 
XO inhibitory activity of compounds A and C in rat liver 
homogenate was assessed using spectroscopic method 
(compound B did not show any inhibition of XO). The 
results of inhibitory activity assay have been tabulated in 
Table 2. 
3.2. Molecular Docking 
The best docking poses were ranked according to the 
scoring function and clustering analysis with regard to 
their relevant binding energy. In Table 3, binding free 
energy, Ki and Gold fitness score of XO inhibitors (A-C) 
were summarized. Binding energy of the compounds A-
C were calculated by consideration of intermolecular 
energy, van der Waals’ energy, hydrogen bonds, 
desolvation free energy, electrostatic hydrogen energy 
(kcal/mol), torsional free energy (kcal/mol) and 
unbound systems energy (kcal/mol). The energetic 
results of docking were shown in Table 3 and the ligand 
binding site of the enzyme was shown by the LIGPLOT 
software as a 2D visualization program (Fig 3). 
 
The results of the docking process and 2D images of 
LIGPLOT showed that the binding site and the number 
of interactions of compound B was different from other 
two derivatives (Figs 2, 3 and 4 and Table 4). The 
observational evidence might explain to some extent the 
different behaviors of compound B vs XO in in vitro 
assay. 
 
Figure 2. 2D scheme of binding interactions between A and XO 
generated by LIGPLOT, PDB deposition code: 3NVY 
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Figure 3. 2D scheme of binding interactions between B and XO 
generated by LIGPLOT, PDB deposition code: 3NVY 
 
 
Figure 4. 2D scheme of binding interactions between C and XO 
generated by LIGPLOT, PDB deposition code: 3NVY 
 
Table 4. Hydrogen bond distances (Å) and location for 1,4-DHP XO 
inhibitors 
Involved amino 
acids 
H bond distance 
(Å) 
atom of the ligand 
A   
Phe1142 2.63 (carbonyl) O 
B   
Thr1122 3.25 (methylene) C 
Thr1135 2.71 (NO2) N 
C   
Leu1138 3.01 (NO2) O 
Lys771 2.64 (NO2) O 
Leu648 3.27 (NO2) N 
 
4. Conclusions 
In the present study, three derivatives of 1,4-DHPs were 
assessed for their cytotoxicity on MCF-7 and L929 cell 
lines from which compound B was found to be toxic on 
both cell lines within 24 and 48 incubation periods. Thus, 
compound B was identified as a candidate for further 
cancer care delivery studies. Moreover, the results of XO 
inhibition assay revealed that unlike the cytotoxicity 
assessment, compound B did not exhibit any inhibitory 
effect on XO enzyme which might be attributed to the 
different binding sites or/and number of interactions 
resulted from molecular docking simulation. Among the 
three derivatives, compound C was the superior XO-
binding molecule which was also confirmed by the 
fitness score of GOLD software. Comparison of the 
binding free energies and XO inhibition constant values 
with that of allopurinol indicated that ∆Gb of the three 
compounds were higher than allopurinol whereas the 
inhibition constant value of allopurinol was superior. 
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